Neurocrine Biosciences (NBIX)
163.12
-0.76 (0.46%)
Upcoming Events
Latest Headlines
Form 4 NEUROCRINE BIOSCIENCES For: Jun 04 Filed by: Norwalk Leslie V
June 8, 2026 6:08 PM - SEC Filing
Neurocrine presents tardive dyskinesia treatment data at conference
June 8, 2026 4:05 PM - StreetInsider
Neurocrine Biosciences Presents New Clinically Meaningful Response Data on Treatment of Tardive Dyskinesia, Reinforcing the Efficacy of INGREZZA® (valbenazine) Capsules Across a Broad Range of Patien
June 8, 2026 4:05 PM - PR NewsWire
Neurocrine presents INGREZZA data for tardive dyskinesia patients
June 8, 2026 8:31 AM - StreetInsider
Neurocrine Biosciences Presents New Data Highlighting Functional and Socio-emotional Improvements with INGREZZA® (valbenazine) Capsules in Individuals with Tardive Dyskinesia and Intellectual and Dev
June 8, 2026 8:30 AM - PR NewsWire
Form 144 NEUROCRINE BIOSCIENCES Filed by: SHERWIN STEPHEN A
June 5, 2026 4:32 PM - SEC Filing
Morgan Stanley tracks prescription trends for US neurology drugs
June 5, 2026 8:59 AM - StreetInsider
Form 4 NEUROCRINE BIOSCIENCES For: Jun 02 Filed by: Cooke Julie
June 4, 2026 6:03 PM - SEC Filing
Form 4 NEUROCRINE BIOSCIENCES For: Jun 02 Filed by: Keswani Sanjay Chandru
June 4, 2026 5:54 PM - SEC Filing
Neurocrine to present two-year CRENESSITY data at medical meeting
June 3, 2026 8:31 AM - StreetInsider
Neurocrine Biosciences to Present New Two‑Year CRENESSITY® (crinecerfont) Data on Key Clinical and Patient‑Reported Outcome Measures at ENDO 2026
June 3, 2026 8:30 AM - PR NewsWire
Form 4 NEUROCRINE BIOSCIENCES For: Jun 01 Filed by: Onyia Jude
June 2, 2026 6:08 PM - SEC Filing
Form 4 NEUROCRINE BIOSCIENCES For: May 29 Filed by: Delaet Ingrid
June 2, 2026 6:03 PM - SEC Filing
Form 144 NEUROCRINE BIOSCIENCES Filed by: Cooke Julie
June 2, 2026 4:39 PM - SEC Filing
Goldman Sachs Resumes Neurocrine Bio. (NBIX) at Buy
June 2, 2026 5:07 AM - StreetInsider
Form 144 NEUROCRINE BIOSCIENCES Filed by: Onyia Jude
June 1, 2026 4:25 PM - SEC Filing
Form 4 NEUROCRINE BIOSCIENCES For: May 27 Filed by: Onyia Jude
May 29, 2026 6:10 PM - SEC Filing
Form 4 NEUROCRINE BIOSCIENCES For: May 27 Filed by: GORMAN KEVIN CHARLES
May 29, 2026 6:06 PM - SEC Filing
Form 4 NEUROCRINE BIOSCIENCES For: May 27 Filed by: POPS RICHARD F
May 29, 2026 6:05 PM - SEC Filing
Form 4 NEUROCRINE BIOSCIENCES For: May 27 Filed by: LYONS GARY A
May 29, 2026 6:05 PM - SEC Filing
Form 4 NEUROCRINE BIOSCIENCES For: May 27 Filed by: Mercier Johanna
May 29, 2026 6:04 PM - SEC Filing
Form 4 NEUROCRINE BIOSCIENCES For: May 27 Filed by: POON CHRISTINE A
May 29, 2026 6:04 PM - SEC Filing
Form 4 NEUROCRINE BIOSCIENCES For: May 27 Filed by: Sharp Shalini
May 29, 2026 6:03 PM - SEC Filing
Form 4 NEUROCRINE BIOSCIENCES For: May 27 Filed by: SHERWIN STEPHEN A
May 29, 2026 6:03 PM - SEC Filing
Form 4 NEUROCRINE BIOSCIENCES For: May 27 Filed by: MORROW GEORGE J
May 29, 2026 6:02 PM - SEC Filing
Form 4 NEUROCRINE BIOSCIENCES For: May 27 Filed by: RASTETTER WILLIAM H
May 29, 2026 6:02 PM - SEC Filing
Form 4 NEUROCRINE BIOSCIENCES For: May 27 Filed by: Norwalk Leslie V
May 29, 2026 6:01 PM - SEC Filing
Form 144 NEUROCRINE BIOSCIENCES Filed by: Delaet Ingrid
May 29, 2026 4:25 PM - SEC Filing
Form 4 NEUROCRINE BIOSCIENCES For: May 26 Filed by: Boyer David W.
May 28, 2026 6:09 PM - SEC Filing
Form 8-K NEUROCRINE BIOSCIENCES For: May 27
May 28, 2026 4:45 PM - SEC Filing
Form 144 NEUROCRINE BIOSCIENCES Filed by: Onyia Jude
May 27, 2026 4:34 PM - SEC Filing
Form 144 NEUROCRINE BIOSCIENCES Filed by: Boyer David W.
May 26, 2026 4:45 PM - SEC Filing
Neurocrine Biosciences to Present at Upcoming Investor Conferences in June
May 26, 2026 4:01 PM - PR NewsWire
Form 4 NEUROCRINE BIOSCIENCES For: May 21 Filed by: SHERWIN STEPHEN A
May 21, 2026 7:25 PM - SEC Filing
Form 4 NEUROCRINE BIOSCIENCES For: May 21 Filed by: Sharp Shalini
May 21, 2026 7:24 PM - SEC Filing
Form 4 NEUROCRINE BIOSCIENCES For: May 21 Filed by: RASTETTER WILLIAM H
May 21, 2026 7:24 PM - SEC Filing
Form 4 NEUROCRINE BIOSCIENCES For: May 21 Filed by: POPS RICHARD F
May 21, 2026 7:23 PM - SEC Filing
Form 4 NEUROCRINE BIOSCIENCES For: May 21 Filed by: POON CHRISTINE A
May 21, 2026 7:23 PM - SEC Filing
Form 4 NEUROCRINE BIOSCIENCES For: May 21 Filed by: Norwalk Leslie V
May 21, 2026 7:22 PM - SEC Filing
Form 4 NEUROCRINE BIOSCIENCES For: May 21 Filed by: MORROW GEORGE J
May 21, 2026 7:22 PM - SEC Filing
Form 4 NEUROCRINE BIOSCIENCES For: May 21 Filed by: Mercier Johanna
May 21, 2026 7:21 PM - SEC Filing
Form 4 NEUROCRINE BIOSCIENCES For: May 21 Filed by: LYONS GARY A
May 21, 2026 7:21 PM - SEC Filing
Form 4 NEUROCRINE BIOSCIENCES For: May 19 Filed by: GORMAN KEVIN CHARLES
May 21, 2026 5:50 PM - SEC Filing
Bernstein SocGen Group Starts Neurocrine Bio. (NBIX) at Outperform
May 21, 2026 4:23 PM - StreetInsider
Form 144 NEUROCRINE BIOSCIENCES Filed by: GORMAN KEVIN CHARLES
May 19, 2026 4:31 PM - SEC Filing
Form 4 NEUROCRINE BIOSCIENCES For: May 15 Filed by: POPS RICHARD F
May 18, 2026 5:51 PM - SEC Filing
Neurocrine presents data on INGREZZA treatment for mild tardive dyskinesia
May 18, 2026 4:06 PM - StreetInsider
Neurocrine Biosciences Presents Real-World Data Highlighting Functional Impact of Mild Tardive Dyskinesia Severity and Improvement with INGREZZA® (valbenazine) Capsules
May 18, 2026 4:05 PM - PR NewsWire
Form 8-K NEUROCRINE BIOSCIENCES For: May 14
May 18, 2026 9:05 AM - SEC Filing
Neurocrine completes $2.9 billion acquisition of Soleno Therapeutics
May 18, 2026 8:47 AM - StreetInsider
Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics
May 18, 2026 8:47 AM - PR NewsWire
Form 144 NEUROCRINE BIOSCIENCES Filed by: POPS RICHARD F
May 15, 2026 4:39 PM - SEC Filing
Form 4 NEUROCRINE BIOSCIENCES For: May 12 Filed by: Norwalk Leslie V
May 14, 2026 4:45 PM - SEC Filing
4basebio appoints Richard Bungay as CFO, announces board changes
May 14, 2026 7:00 AM - StreetInsider
Form 144 NEUROCRINE BIOSCIENCES Filed by: Norwalk Leslie V
May 12, 2026 2:36 PM - SEC Filing
Neurocrine Bio. (NBIX) PT Raised to $155 at Truist Securities
May 6, 2026 1:16 PM - StreetInsider
Neurocrine publishes expert guidelines for glucocorticoid reduction with CRENESSITY
May 6, 2026 8:32 AM - StreetInsider
Neurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction after Initiating CRENESSITY® (crinecerfont) for the Treatment of Classic Congenital Adrenal Hy
May 6, 2026 8:30 AM - PR NewsWire
Neurocrine Bio. (NBIX) PT Raised to $191 at Morgan Stanley
May 6, 2026 8:14 AM - StreetInsider
Neurocrine Bio. (NBIX) PT Raised to $144 at BMO Capital
May 6, 2026 8:03 AM - StreetInsider
Neurocrine Bio. (NBIX) PT Raised to $207 at Piper Sandler
May 6, 2026 7:15 AM - StreetInsider
Neurocrine Bio. (NBIX) PT Raised to $180 at RBC Capital
May 6, 2026 6:40 AM - StreetInsider
Neurocrine Bio. (NBIX) PT Raised to $176 at Wedbush
May 6, 2026 6:33 AM - StreetInsider
Neurocrine Bio. (NBIX) PT Raised to $230 at Oppenheimer
May 6, 2026 6:11 AM - StreetInsider
Neurocrine Biosciences (NBIX) Tops Q1 EPS by 77c, Beats on Revenue
May 5, 2026 4:14 PM - StreetInsider
Form 10-Q NEUROCRINE BIOSCIENCES For: Mar 31
May 5, 2026 4:04 PM - SEC Filing
Form 8-K NEUROCRINE BIOSCIENCES For: May 05
May 5, 2026 4:02 PM - SEC Filing
Neurocrine Biosciences Reports First-Quarter 2026 Financial Results
May 5, 2026 4:01 PM - PR NewsWire
Neurocrine Biosciences to Present at the Bank of America Health Care Conference 2026
May 5, 2026 9:00 AM - PR NewsWire
Neurocrine Biosciences Announces New Survey Results Showing Significant Burden of Tardive Dyskinesia on Employment
May 4, 2026 8:30 AM - PR NewsWire
Neurocrine begins phase 1 trial of obesity drug targeting new mechanism
May 4, 2026 7:30 AM - StreetInsider
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'2118, a Corticotropin-Releasing Factor Type 2 Receptor Agonist
May 4, 2026 7:30 AM - PR NewsWire
Neurocrine shows sustained pediatric results for CRENESSITY in two-year study
May 1, 2026 4:06 PM - StreetInsider
Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Durable Hormone Control, Reduced Glucocorticoid Exposure and Meaningful Clinical Improvements in Pediatric P
May 1, 2026 4:05 PM - PR NewsWire
Form SCHEDULE 13G NEUROCRINE BIOSCIENCES Filed by: VANGUARD CAPITAL MANAGEMENT LLC
April 30, 2026 11:41 AM - SEC Filing
Neurocrine publishes tardive dyskinesia scale validation research
April 29, 2026 4:07 PM - StreetInsider
Neurocrine Biosciences Announces Publication Establishing Clinically Meaningful Improvement Threshold for the Tardive Dyskinesia Impact Scale
April 29, 2026 4:05 PM - PR NewsWire
Neurocrine Bio. (NBIX) PT Raised to $200 at Needham
April 24, 2026 8:44 AM - StreetInsider
Neurocrine reports sustained dose reductions with CRENESSITY in CAH patients
April 22, 2026 4:05 PM - StreetInsider
Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Showing Sustained Glucocorticoid Dose Reductions While Maintaining Androgen Control in Adults with Classic Congenital Adre
April 22, 2026 4:05 PM - PR NewsWire
Form ARS NEUROCRINE BIOSCIENCES For: Dec 31
April 15, 2026 4:19 PM - SEC Filing
Form DEFA14A NEUROCRINE BIOSCIENCES
April 15, 2026 4:18 PM - SEC Filing
Form DEF 14A NEUROCRINE BIOSCIENCES For: Apr 15
April 15, 2026 4:16 PM - SEC Filing
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2026 Financial Results
April 14, 2026 4:01 PM - PR NewsWire
INGREZZA shows higher treatment persistence than AUSTEDO XR in study
April 14, 2026 8:32 AM - StreetInsider
Neurocrine Biosciences Presents First Real-World Head-to-Head Claims Analysis Demonstrating Greater Treatment Persistence with INGREZZA® (valbenazine) Capsules Compared to AUSTEDO XR
April 14, 2026 8:30 AM - PR NewsWire
Neurocrine Bio. (NBIX) PT Raised to $185 at Morgan Stanley
April 10, 2026 6:06 AM - StreetInsider
Neurocrine Bio. (NBIX) PT Raised to $215 at H.C. Wainwright
April 8, 2026 7:11 AM - StreetInsider
Neurocrine Bio. (NBIX) PT Lowered to $176 at RBC Capital
April 7, 2026 9:02 AM - StreetInsider
Neurocrine Bio. (NBIX) PT Raised to $242 at Citi
April 7, 2026 5:01 AM - StreetInsider
Neurocrine Bio. (NBIX) PT Raised to $166 at Wedbush
April 6, 2026 3:49 PM - StreetInsider
Neurocrine Bio. (NBIX) PT Raised to $200 at Canaccord
April 6, 2026 2:41 PM - StreetInsider
Neurocrine Bio. (NBIX) PT Raised to $220 at Oppenheimer on SLNO deal
April 6, 2026 1:59 PM - StreetInsider
Baird on Neurocrine Bio's Soleno deal: Incrementally positive on acquisition
April 6, 2026 1:10 PM - StreetInsider
UBS Reiterates Buy Rating on Neurocrine Bio. (NBIX) Following Reports of Soleno Acquisition
April 6, 2026 9:35 AM - StreetInsider
Form 8-K NEUROCRINE BIOSCIENCES For: Apr 05
April 6, 2026 7:35 AM - SEC Filing
Neurocrine expands into metabolic diseases with $2.9 billion Soleno buyout
April 6, 2026 7:07 AM - StreetInsider
Neurocrine to acquire Soleno Therapeutics for $2.9 billion in cash deal
April 6, 2026 7:01 AM - StreetInsider
Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio
April 6, 2026 7:00 AM - PR NewsWire
Neurocrine Biosciences nearing over $2.5B deal for Soleno Therapeutics
April 6, 2026 5:53 AM - StreetInsider
Form SCHEDULE 13G/A NEUROCRINE BIOSCIENCES Filed by: VANGUARD GROUP INC
March 27, 2026 10:51 AM - SEC Filing
Neurocrine presents tardive dyskinesia treatment guidance for elderly
March 26, 2026 8:33 AM - StreetInsider
Neurocrine Biosciences Presents First Expert Consensus Recommendations for Tardive Dyskinesia in Long-Term Care Settings
March 26, 2026 8:30 AM - PR NewsWire
Form 3 NEUROCRINE BIOSCIENCES For: Mar 15 Filed by: Ratz Andrew
March 17, 2026 5:57 PM - SEC Filing
Neurocrine Biosciences promotes Andrew Ratz to chief technical operations officer
March 17, 2026 4:09 PM - StreetInsider
Neurocrine Biosciences Appoints Andrew Ratz, Ph.D., as Chief Technical Operations Officer
March 17, 2026 4:06 PM - PR NewsWire
Neurocrine Bio. (NBIX) PT Raised to $177 at JPMorgan
March 12, 2026 8:43 AM - StreetInsider
Full Article List
